Company / R&D Expense
Indivior R&D Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$97.0M
FY2025
5-year range
$74.0M / $116.0M
FY2022-FY2025
Trend
-9.3%
vs FY2024
Sector context
#143 of 210
Health Care
What the data says
At $97M, Indivior's r&d expense ranks #143 of 210 in the Health Care sector. Declined from $116M to $97M over the past 2 years.
Based on SEC 10-K filings.
$97M in FY2025 with a 3-year CAGR of +9.4%.
Declined from $116M to $97M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +9.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#143 of 210 in Health CareTop 68% of 210This company $97.0M Sector average $644.1M
▼
-84.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +9.4%, indicating consistent growth.
- In FY2025, r&d expense decreased 9.3% year-over-year.
- Ranks #143 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $97.0M | -9.3% |
| FY2024 | $107.0M | -7.8% |
| FY2023 | $116.0M | +56.8% |
| FY2022 | $74.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026